AHCPR: LHRH agonists are equally effective

March 1999
Urology Times;Mar99, Vol. 27 Issue 3, p3
Cites an Agency for Health Policy Research report which said that luteinizing hormone-releasing agonists produce roughly the same survival and side effects in men with advanced prostate cancer, regardless of which of the testosterone-suppressing drugs is taken.


Related Articles

  • The treatment of advanced prostate cancer with ketoconazole: safety issues. Bok, R.A.; Small, E.J. // Drug Safety;May1999, Vol. 20 Issue 5, p451 

    The definition of hormone refractory prostate cancer is changing. It has become clear that patients with advanced prostate cancer whose disease has progressed following treatment with luteinising hormone releasing hormone agonists and antiandrogens can respond to additional hormonal manoeuvres....

  • Medicare Reimbursement and Prescribing Hormone Therapy for Prostate Cancer. Keating, Nancy L. // JNCI: Journal of the National Cancer Institute;Dec2010, Vol. 102 Issue 24, p1814 

    The author ponders on the findings of a study on the use of gonadotropin-releasing hormone (GnRH) agonists for prostate cancer treatment, by Elliott and colleagues, published within the issue. The study assessed if the decreased reimbursements to providers resulting from the Medicare...

  • Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer. Smith, Matthew R.; McGovern, Francis J.; Zietman, Anthony L.; Fallon, Mary Anne; Hayden, Douglas L.; Schoenfeld, David A.; Kantoff, Philip W.; Finkelstein, Joel S. // New England Journal of Medicine;9/27/2001, Vol. 345 Issue 13, p948 

    Background: Treatment with a gonadotropin-releasing hormone agonist decreases bone mineral density and increases the risk of fracture in men with prostate cancer. We conducted a controlled study of the prevention of osteoporosis in men undergoing treatment with a gonadotropin-releasing hormone...

  • Drugs in Clinical Development for Prostate Cancer.  // Pharmaceutical Medicine - New Zealand;2011, Vol. 25 Issue 6, p387 

    The article offers information on the drugs that are in clinical development for prostate cancer. The treatment options available for patients with prostate cancer are discussed. Also mentioned are the risks associated with estrogen therapy and luteinizing hormone-releasing hormone (LHRH)...

  • Antithrombin III concentration, thrombosis, and treatment with luteinising hormone releasing hormone agonist in prostatic carcinoma. Varenhorst, E.; Svensson, M.; Hjertberg, H.; Malmqvist, E. // British Medical Journal (Clinical Research Edition);4/5/1986, Vol. 292 Issue 6525, p935 

    Investigates the effects of luteinising hormone releasing hormone agonist used in treating prostatic carcinoma. Observation on the fall in plasma antithrombin III concentration; Measurement of plasma antithrombin concentration before and during treatment; Estimation on the risk of...

  • Drop in reimbursement led to drop in inappropriate ADT use.  // PharmacoEconomics & Outcomes News;1/8/2011, Issue 619, p6 

    The article discusses research on the link between the use of androgen deprivation therapy (ADT) and reimbursement for gonadotropin releasing hormone (GnRH) agonists in the U.S., by V. B. Shahinian and colleagues, published in the "New England Journal of Medicine."

  • Towards healthier infertility. Judson, Olivia P. // Nature;9/2/1993, Vol. 365 Issue 6441, p15 

    Discusses the results of a two-year pilot trial on a contraceptive based on a gonadotropin-releasing hormone agonist. Reduction of the relative risk of breast cancer; Absence of premenstrual syndrome; Addition of oestrogen and progesterone pills to the regimen to avoid bone loss associated with...

  • Comparison of efficacy and safety of 1- and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer. Ishizuka, Osamu; Nishizawa, Osamu; Nishizawa, Shuji; Satoh, Tomoya; Wajiki, Masahisa; Kiyokawa, Hideo; Inoue, Yoshihiro; Kobayashi, Shinya; Mizusawa, Hiroya; Nakagawa, Tatsuo // International Journal of Clinical Oncology;Jun2013, Vol. 18 Issue 3, p524 

    Background: We compared the efficacy and safety of 1- and 3-month depots of the luteinizing hormone-releasing hormone (LH-RH) agonist goserelin acetate in prostate cancer patients. Methods: Patients were randomly assigned to the Direct Group that received the goserelin 3-month depot or the...

  • Use of combined androgen blockade for advanced prostate cancer in British Columbia. Chau, Adeline; de Lemos, M├írio L.; Pickles, Tom; Blood, Paul; Kovacic, Laurel; Abadi, Shirin; Barnett, Jeff // Journal of Oncology Pharmacy Practice;Jun2010, Vol. 16 Issue 2, p121 

    Objectives. Initial androgen deprivation therapy (ADT) for metastatic prostate cancer with combined androgen blockade (luteinizing-hormone releasing hormone agonist [LHRH agonist] plus antiandrogen) is not recommended in British Columbia (BC). However , this is difficult to monitor since ADT...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics